Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer
ConclusionsWe confirm safety and efficacy of osimertinib with high response rates among all subgroups, including patients with poor performance status and multiple prior therapy lines. Amplification ofMET might mediate acquired resistance to osimertinib.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Germany Health | Lung Cancer | Non-Small Cell Lung Cancer | Toxicology